SPG4 Founder Effect in French Canadians with Hereditary Spastic Paraplegia
Inge. A. Meijer, Nicolas Dupré, Bernard Brais, Patrick Cossette, Judith St-Onge, Marie-France Rioux, Melanie Benard, Guy A. Rouleau gene encodes spastin, which has been implicated in various processes such as endosomal trafficking and cytoskeletal rearrangement, but the most studied function is microtubule severing 13 through its MIT (microtubule-interacting and trafficking molecules) domain 14 and the AAA (ATPase associated with various cellular activities) domain. Since the cloning of the SPG4 gene, 15 over 150 mutations have been reported across the gene. [16] [17] [18] The majority of missense mutations occur in the AAA cassette including the c.G1801A mutation we previously reported in two French Canadian (FC) families. 19, 20 In this study we determine the relative frequency of the c.G1801A mutation in our French Canadian collection, we provide evidence that the subjects carrying this mutation originate from a common ancestor, and we describe the associated phenotypic features.
METHODS

Subjects
Subjects gave written informed consent to participate in our study, which was approved by the local ethics review board (Centre Hospitalier de l'Université de Montréal). Peripheral blood samples were obtained from 37 probands and DNA was extracted by standard methods. Probands were recruited through their treating neurologist, who had performed a complete neurological examination, spinal magnetic resonance imaging, and basic blood tests. Their chart was thereafter reviewed by a neurologist (ND) with expertise in HSP. French Canadian ancestry was determined by establishing that parents and grandparents of the probands were of FC descent.
Genotyping
Polymorphic markers were amplified by PCR incorporating radiolabeled S 35 dATP into the product. The products were separated on 6% denaturing polyacrylamide gels and visualized on autoradiographic film. The following markers were genotyped in and around the SPG4 gene: D2S2201, D2S1383, D2S352, D2S2347, D2S367, D2S1325, and D2S2328. Haplotype construction assuming minimal recombination was performed manually and ordered according to the goldenpath physical map (http://www.genome.ucsc.edu/).
Mutation Detection
Exon 15 was amplified using flanking primers previously reported by Meijer et al 2001 20 and PCR products were sequenced at the McGill University and Genome Quebec Centre for Innovation.
RESULTS
We have previously identified spastin mutations in 15 North
American families including 8 novel mutations and 2 recurring mutations in Caucasian families. 20 The c.G1801A mutation was detected in 2 out of 32 FC probands, which was suggestive of a common FC mutation. In the present study we have collected and sequenced another 37 families for this mutation in exon 15. We identified three additional families with the common c.G1801A mutation (Figure) . The c.G1801A mutation therefore has a 7% frequency (5/69) in our FC sample. This also represents approximately half of the spastin mutations found in the FC cohort. To determine whether the families share the mutation because of a genetic link or because of a mutational hotspot, we performed haplotype analysis around the SPG4 locus ( Table 1) . The haplotype analysis indicates that all five families share a segment of at least 4 Mb and thus originate from a common ancestor. Unfortunately, insufficient archival data did not permit genealogical studies for these five families.
The phenotype associated with this mutation is that of pure HSP with or without bladder involvement ( Table 2 ). The age of onset varies greatly between families and mild sensory symptoms are only seen in two probands. For subject R19935, detailed clinical information was not available, but this patient was diagnosed with pure adult onset HSP by the treating neurologist, and had a family history of pure HSP.
DISCUSSION
We have identified the first common spastin mutation in Quebec, which is suggestive of a founder effect. This c.G1801A mutation has not been reported by other groups and seems to be specific to the FC population. Our laboratory has the largest collection of FC HSP cases and the c.G1801A mutation is the only recurring HSP mutation in this population, with a frequency of 7%. The other genetic causes for HSP in Quebec include mutations in: PLP (1 family), atlastin (1 family), spastin (6 families/6 mutations) and SPG27 (1 family), but they all occur at a much lower frequency 20, 21 (personal communication). Interestingly, the frequency of spastin mutations in our French-Canadian collection is lower than the 40% that is usually reported. 15 Several other groups have reported lower spastin frequencies in their cohorts for example 19%, 22 22%, 23 and 17%. 24 A possible explanation for this discrepancy is that all these studies did not select for spastin linked families. Alternatively, given the French Canadian founder effect, spastin mutations may simply have been introduced at a lower frequency in the founders. In addition, our cohort might include more sporadic cases which have a lower spastin mutation rate, 12 or there is a higher number of micro-deletions in our samples which we could not detect with the available methods. 25 Founder mutations have previously been studied in French Canada because of historical roots of the populations and many genes have been identified for these mostly recessive diseases such as Autosomal Recessive Spastic Ataxia of CharlevoixSaguenay and Hereditary Motor and Sensory neuropathy with Agenesis of the Corpus Callosum. 26, 27 The c.G1801A mutation is one of the few examples of a common ancestor in Quebec for a dominant disease. Another example is Clouston hidrotic ectodermal dyspasia, where a 1.3 cM common haplotype was found in French-Canadian families. 28 The only other reported founder mutation in spastin was reported by Orlacchio et al. 29 The p.N386S change was detected in 9/15 Scottish families and those families shared a ~ 9 Mb haplotype. Recently, Namekawa and colleagues 30 also showed evidence of a common ancestor for the R495W atlastin mutation in the French population.
The phenotype associated with SPG4 mutations is very variable and mutation carriers can present with pure HSP, ataxia, 31 Primary Lateral Sclerosis (PLS), early onset Amyotrophic Lateral Sclerosis (ALS), 32 or dyplastic corpus callosum. 33 The probands with the c.G1801A mutation present with a pure form of HSP and the disease is uniform in all five families. In addition, the penetrance associated with this mutation is likely complete since all identified mutation carriers have HSP. Even though the FC HSP population is genetically diverse, it is advisable to screen for the c.G1801A mutation as a priority in patients with dominant or sporadic adult onset HSP to improve efficiency of genetic testing. Interestingly, successful prenatal diagnosis for spastin mutations has been reported and offers an option for families with severe early onset HSP. A recent report showed that in a Drosophila model of spastin with adult onset neurodegeneration, the phenotype was partially alleviated by treatment with vinblastine, a modulator of microtubule stability. 35 These findings offer hope for the development of a treatment for spastin related HSP and further underlines the importance of testing for spastin mutations.
